0001415889-23-012132.txt : 20230811
0001415889-23-012132.hdr.sgml : 20230811
20230811161031
ACCESSION NUMBER: 0001415889-23-012132
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230811
FILED AS OF DATE: 20230811
DATE AS OF CHANGE: 20230811
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shaff Eric D.
CENTRAL INDEX KEY: 0001643734
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39746
FILM NUMBER: 231164170
MAIL ADDRESS:
STREET 1: C/O SERES HEALTH, INC.
STREET 2: 161 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sigilon Therapeutics, Inc.
CENTRAL INDEX KEY: 0001821323
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474005543
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 BINNEY STREET
STREET 2: STE 600
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-336-7540
MAIL ADDRESS:
STREET 1: 100 BINNEY STREET
STREET 2: STE 600
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
form4-08112023_040813.xml
X0508
4
2023-08-11
0001821323
Sigilon Therapeutics, Inc.
SGTX
0001643734
Shaff Eric D.
C/O SIGILON THERAPEUTICS, INC.
100 BINNEY STREET STE 600
CAMBRIDGE
MA
02142
true
false
false
false
0
Stock Option (Right to Buy)
8.2761
2023-08-11
4
D
0
683
6.6439
D
2033-05-18
Common Stock
683
0
D
Stock Option (Right to Buy)
9.9216
2023-08-11
4
D
0
683
4.9984
D
2032-05-25
Common Stock
683
0
D
Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split.
Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time.
Capitalized terms used herein without definition have the meanings ascribed to them in the Agreement and Plan of Merger, dated as of June 28, 2023, among Sigilon Therapeutics, Inc., Eli Lilly and Company and Shenandoah Acquisition Corporation. (the "Merger Agreement").
/s/ Matthew Kowalsky, Attorney-in-Fact
2023-08-11